These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19679004

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ribosome-component immune modulation of respiratory tract infections in adults.
    Olivieri D, Chiesa S, Tzani P, Marino P, Robberto E, Marcassa S.
    Allergy Asthma Proc; 2009; 30 Suppl 1():S13-9. PubMed ID: 19679001
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children.
    Fiocchi A, Omboni S, Mora R, Macchi A, Nespoli L, Arrigoni S, Guastini L, Castelnuovo P, Graziani D, Marcassa S.
    Allergy Asthma Proc; 2012; 33(2):197-204. PubMed ID: 22525398
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults.
    Berdeaux G, Lafuma A, Perruchet AM, Fagnani F.
    Pharmacoeconomics; 1998 Sep; 14(3):313-22. PubMed ID: 10186469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use.
    Lambert S, O'Grady KA, Gabriel S, Carter R, Nolan T.
    Commun Dis Intell Q Rep; 2004 Sep; 28(4):510-6. PubMed ID: 15745401
    [Abstract] [Full Text] [Related]

  • 8. [Immunoprophylaxis of infections of the upper respiratory tract in the frequently ill children].
    Karpova EP, Zaplatnikov AL, Tulupov DA.
    Vestn Otorinolaringol; 2015 Sep; 80(5):80-84. PubMed ID: 26525479
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections.
    Banz K, Schwicker D, Thomas AM.
    Pharmacoeconomics; 1994 Nov; 6(5):464-77. PubMed ID: 10155274
    [Abstract] [Full Text] [Related]

  • 10. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.
    Mahadevia PJ, Strell J, Kunaprayoon D, Gelfand E.
    Value Health; 2005 Nov; 8(4):488-94. PubMed ID: 16091026
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I, Daudon M, Molinier L, Tack I, Nuijten MJ.
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
    Simoens S.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ribosome-component immune modulator for preventing recurring respiratory infections in socialized children.
    Bergamini M, Simeone G, Verga MC, Fiocchi A, Omboni S.
    Allergy Asthma Proc; 2013 Aug; 34(1):108-9. PubMed ID: 23406944
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rationale for the clinical use of a ribosome-component immune modulator.
    Pregliasco F, Terracciano L, Marcassa S, Zava D, Anselmi G.
    Allergy Asthma Proc; 2009 Aug; 30 Suppl 1():S5-12. PubMed ID: 19679000
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.